Greenovation
is a Private company. Andreas Schaaf is the Managing Director of Greenovation and has an approval rating of 90 from Owler members. Greenovation has 3 followers on Owler.Greenovation
is a Private company. Andreas Schaaf is the Managing Director of Greenovation and has an approval rating of 90 from Owler members. Greenovation has 3 followers on Owler.
News
Feb 07, 2017
Business Wire
Press Release: Greenovation : Gaucher Disease - Pipeline Review, H2 2016 - Therapeutics Assessment by Drug Target, MoA, RoA & Molecule Type - Research and Markets
Oct 24, 2016
BioPortfolio
Greenovation: Mossbased manufacturing technology enhances pharmaceutical protein yield
Jun 16, 2016
Business Wire
Press Release: Greenovation : Glucosylceramidase (Acid Beta-Glucosidase or Alglucerase or D-Glucosyl-N-Acylsphingosine Glucohydrolase or EC 3.2.1.45) - Pipeline Review, H1 2016 - Research and Markets
Oct 01, 2015
BIOPORTFOLIO
Greenovation: Greenovation Receives BfArM Approval to Start Phase I Clinical Trial for MossaGal the WorldÂs First MossProduced Drug Candidate
Sep 14, 2015
BIOSPACE
Greenovation: greenovation Biotech GmbH Receives BfArM Approval To Start Phase I Clinical Trial For Moss-Agal, The World's First Moss-Produced Drug Candidate
Aug 27, 2015
BIOSPACE
Greenovation: greenovation Biotech GmbH Release: Fabry Enzyme Replacement Therapy (ERT) Based On Mannose-Mediated Cellular Uptake Shows Encouraging Preclinical Results That Allow Start Of Early Clinical Trials
Apr 10, 2015
BIOPORTFOLIO
Greenovation: Greenovation Successfully Completes Preclinical Toxicology Studies of Alpha Galactosidase
Mar 11, 2015
BIOSPACE
Greenovation: <b>Greenovation Biotech GmbH</b> Successfully Completes Preclinical Toxicology Studies Of Alpha - Galactosidase
Oct 20, 2014
BIOPORTFOLIO
Greenovation: First GMPCompliant Batch of a Biologic Drug Substance from a Moss Expression System Produced for Clinical Use
Jun 12, 2014
BIOSPACE
Greenovation: Positive Preclinical Performance Of greenovation Biotech GmbH`s Lead Candidate moss-?Gal